NCT07432932Recruiting
Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients
Source: ClinicalTrials.gov · Last updated 25 Feb 2026
Brief summary (registry, in English)
This is a cohort study aimed at developing a stratified medicine approach for personalised neoadjuvant chemotherapy (NCT) in high-risk soft tissue sarcoma (STS) patients with dedifferentiated liposarcoma (DDLPS), leiomyosarcoma (LMS), synovial sarcoma (SS), vascular sarcomas, malignant peripheral nerve sheath tumour (MPNST) or other subtypes. It comprises of both retrospective and prospective tissue collection from patients advancing directly to surgery (control group) and patients receiving NCT and surgery.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 800 (estimated)
- First submitted
- 26 May 2022
- Start date
- 19 Nov 2021
- Primary completion date
- 31 Mar 2026
- Lead sponsor
- Royal Marsden NHS Foundation Trust
- Diseases
- Sarcoma
- NCT number
- NCT07432932
- EudraCT number
- 2021-001437-39
What you commit to
- Study type: Observational
- Planned participants: 800
- From 19 Nov 2021 to the primary completion date, 31 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- -Prior invasive malignancy in last 5 years, low risk malignancies in the last 5 years may be reviewed by the PI.
- Known additional malignancy that is progressing or requires active treatment
- Metastatic disease not amenable to curative intent local therapy
- Any active uncontrolled medical conditions
Who the study is looking for
- Written informed consent for the prospective cohort
- Histopathological diagnosis of high-risk soft tissue sarcoma and one of the following subtypes: DDLPS, LMS, SS, vascular sarcomas or MPNST. Other subtypes may be included with PI approval.
- High-risk sarcoma definition:
- Greater than 5cm or Grade 3
- Deep anatomic location
- Have disease amenable to biopsy
- o Patients who are not amenable to repeat biopsy at baseline can be reviewed with the local site PI for consideration of inclusion to the study
- Resectable tumour
- Measurable disease by RECIST 1.1
- Aged ≥ 18 years
- WHO performance status 0-2
- For patients receiving NCT, medically fit enough, with adequate organ function, to undergo neoadjuvant chemotherapy
- Patients medically fit enough to undergo surgical resection
- Capable of giving written informed consent (for prospective cohort) and comply with the study schedule
- Patients may also participate in the STRASS 2 trial
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Royal Marsden Hospital Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.